FDA Approves Bemotrizinol as First New Sunscreen Ingredient in the US in 20 Years

The US Food and Drug Administration has approved bemotrizinol as a new sunscreen active ingredient, marking the first addition to the country’s approved UV filter list in roughly two decades.

The approval ends a long regulatory impasse that had kept American consumers from accessing a sunscreen ingredient already common in Europe, Australia and parts of Asia for well over a decade. Bemotrizinol, known commercially as Tinosorb S in international markets, provides broad-spectrum protection against both UVA and UVB radiation. The FDA has approved concentrations of up to six percent in sunscreen formulations.

The ingredient’s absence from the US market had frustrated dermatologists for years. They had argued that American consumers were using outdated UV filters compared to options available elsewhere. The FDA’s sunscreen monograph system, which governs over-the-counter sunscreen ingredients, had not added a new active ingredient since before 2006, leaving the US with a narrow list that most other developed countries had long expanded.

Unlike most existing US-approved UV filters, which primarily absorb ultraviolet light, bemotrizinol uses a combination of absorption and reflection to neutralize UV radiation. Studies have shown it to be photostable, meaning its effectiveness does not degrade significantly with sunlight exposure — a known problem with some older filters such as avobenzone when used without stabilizers.

Dermatology groups have welcomed the approval. Several major sunscreen brands indicated they are already preparing new US formulations, with some products expected on shelves within 12 months. The FDA’s decision also signals a potential acceleration for other internationally approved UV filters currently under review.

Americans spend more than $1.5 billion on sunscreen products annually. Skin cancer remains the most common cancer in the United States, with over five million cases diagnosed each year. Dermatologists have long maintained that better UV filters could meaningfully improve prevention rates for certain skin cancer types.

This approval is part of a broader moment for health research translating into clinical access. A Stanford arthritis study earlier this month showed how experimental treatments are moving closer to patients faster than before. Separately, large-scale data on strength training benefits reinforced how consistent lifestyle choices carry long-term protective effects.

The FDA’s OTC drug page provides technical details of the bemotrizinol approval, including permitted concentrations and testing requirements for manufacturers entering the US market.

Consumer groups are now urging the FDA to accelerate review of other internationally approved UV filters still waiting for US clearance, arguing that the bemotrizinol decision proves the process can move when the pressure is sufficient.